MCID: SKN019
MIFTS: 69

Skin Melanoma

Categories: Cancer diseases, Skin diseases, Ear diseases

Aliases & Classifications for Skin Melanoma

MalaCards integrated aliases for Skin Melanoma:

Name: Skin Melanoma 12 55 15
Cutaneous Melanoma 12 29 6 73
Malignant Melanoma of Ear and/or External Auricular Canal 12
Malignant Melanoma of Skin of Trunk Except Scrotum 12
Malignant Melanoma of Skin of Lower Limb 12
Malignant Melanoma of Skin of Upper Limb 12
Melanoma, Cutaneous Malignant 44
Malignant Lower Limb Melanoma 12
Malignant Upper Limb Melanoma 12
Malignant Scalp Melanoma 12
Malignant Trunk Melanoma 12
Malignant Neck Melanoma 12
Malignant Ear Melanoma 12
Malignant Lip Melanoma 12
Melanoma 73

Classifications:



Summaries for Skin Melanoma

Disease Ontology : 12 A skin cancer that has material basis in melanocytes.

MalaCards based summary : Skin Melanoma, also known as cutaneous melanoma, is related to melanoma, cutaneous malignant 1 and amelanotic melanoma, and has symptoms including exanthema and pruritus. An important gene associated with Skin Melanoma is NRAS (NRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Mekinist and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Skin Melanoma

Diseases related to Skin Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 150)
# Related Disease Score Top Affiliating Genes
1 melanoma, cutaneous malignant 1 33.8 CDK4 CDKN2A CDKN2B HRAS MITF NRAS
2 amelanotic melanoma 33.1 BRAF KIT TYR
3 acral lentiginous melanoma 32.9 BRAF CDKN2A KIT NRAS PTEN
4 melanoma 31.5 BRAF CDK4 CDKN2A FBN1 MAP2K1 MITF
5 squamous cell carcinoma 29.9 BRAF CDKN2A CTNNB1 HRAS PIK3CA PTEN
6 melanoma, cutaneous malignant 2 12.4
7 melanoma, cutaneous malignant 3 12.4
8 melanoma, cutaneous malignant 5 12.4
9 melanoma, cutaneous malignant 6 12.4
10 melanoma, cutaneous malignant 9 12.4
11 melanoma, cutaneous malignant 10 12.4
12 melanoma, cutaneous malignant 8 12.4
13 melanoma, cutaneous malignant 4 12.2
14 melanoma, cutaneous malignant 7 12.2
15 skin/hair/eye pigmentation, variation in, 3 11.2
16 giant congenital nevus 11.2 HRAS NRAS
17 spitz nevus 11.2 BRAF CDKN2A HRAS
18 breast angiosarcoma 11.2 KIT MITF TYR
19 malignant spindle cell melanoma 11.1 KIT MITF NRAS TYR
20 differentiated thyroid carcinoma 11.1 BRAF CDKN2A HRAS NRAS
21 angiomyolipoma 11.1 KIT MITF TYR
22 thymoma, familial 11.1 HRAS KIT
23 neurofibroma 11.1 CDKN2A KIT MITF
24 albinism, ocular, with sensorineural deafness 11.1 MITF TYR
25 langerhans cell histiocytosis 11.1 BRAF MAP2K1 NRAS
26 rare isolated myopia 11.1 FBN1 TYR
27 dyschromatosis symmetrica hereditaria 11.0 HRAS MITF TYR
28 erdheim-chester disease 11.0 BRAF NRAS PIK3CA
29 skin sarcoma 11.0 CDK4 CDKN2B MITF
30 phakomatosis cesioflammea 11.0 GNA11 GNAQ
31 vulvar melanoma 11.0 HRAS KIT NRAS TYR
32 core binding factor acute myeloid leukemia 11.0 HRAS KIT NRAS
33 malignant skin fibrous histiocytoma 11.0 HRAS KIT NRAS TYR
34 malignant dermis tumor 11.0 HRAS KIT NRAS TYR
35 pulmonic stenosis 11.0 BRAF HRAS MAP2K1
36 conjunctival cancer 11.0 GNA11 GNAQ NRAS
37 conventional fibrosarcoma 11.0 CTNNB1 KIT NRAS
38 gallbladder adenoma 11.0 CDKN2A CTNNB1 HRAS
39 meningeal melanocytoma 10.9 CDKN2A GNA11 GNAQ NRAS
40 ewing's family of tumors 10.9 CDK4 CDKN2A CDKN2B KIT
41 intraocular melanoma 10.9 GNA11 GNAQ
42 cardiofaciocutaneous syndrome 1 10.9 BRAF HRAS MAP2K1
43 liver angiosarcoma 10.9 CDK4 HRAS NRAS
44 noonan syndrome 1 10.9 BRAF HRAS MAP2K1 NRAS
45 fibrosarcoma of bone 10.9 CDK4 CDKN2A KIT
46 benign struma ovarii 10.9 HRAS NRAS
47 melanocytic nevus syndrome, congenital 10.9 HRAS NRAS STK11 TYR
48 nevus, epidermal 10.9 HRAS NRAS PIK3CA
49 grade iii astrocytoma 10.9 CDK4 CDKN2A CDKN2B PTEN
50 dowling-degos disease 1 10.9 KIT MITF STK11 TYR

Graphical network of the top 20 diseases related to Skin Melanoma:



Diseases related to Skin Melanoma

Symptoms & Phenotypes for Skin Melanoma

UMLS symptoms related to Skin Melanoma:


exanthema, pruritus

GenomeRNAi Phenotypes related to Skin Melanoma according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.96 HRAS PIK3CA
2 Decreased viability GR00221-A-1 9.96 PIK3CA CDKN2A HRAS KIT NRAS
3 Decreased viability GR00221-A-2 9.96 PIK3CA HRAS
4 Decreased viability GR00221-A-3 9.96 CDKN2A HRAS NRAS
5 Decreased viability GR00221-A-4 9.96 PIK3CA CDKN2A
6 Decreased viability GR00301-A 9.96 KIT
7 Decreased viability GR00402-S-2 9.96 PIK3CA CDKN2A HRAS KIT NRAS
8 Decreased cell migration GR00055-A-1 9.77 CTNNB1 HRAS BRAF CDK4 PIK3CA
9 Decreased substrate adherent cell growth GR00193-A-1 9.76 KIT
10 Decreased substrate adherent cell growth GR00193-A-2 9.76 KIT CDK4
11 Decreased substrate adherent cell growth GR00193-A-3 9.76 BRAF CDK4
12 Decreased substrate adherent cell growth GR00193-A-4 9.76 CDK4 KIT BRAF
13 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.73 PTEN CTNNB1 STK11 HRAS NRAS CDK4
14 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.5 STK11 BRAF CDK4
15 Increased cell migration GR00055-A-3 8.92 PIK3CA CTNNB1 HRAS BRAF

MGI Mouse Phenotypes related to Skin Melanoma:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.53 MAP2K1 KIT PIK3CA NRAS MITF TYR
2 behavior/neurological MP:0005386 10.51 KIT HRAS MITF PIK3CA NRAS STK11
3 cardiovascular system MP:0005385 10.5 MAP2K1 KIT HRAS PIK3CA NRAS STK11
4 homeostasis/metabolism MP:0005376 10.5 MAP2K1 KIT HRAS PIK3CA NRAS MITF
5 growth/size/body region MP:0005378 10.49 MAP2K1 KIT HRAS MITF PIK3CA NRAS
6 integument MP:0010771 10.48 MAP2K1 KIT PIK3CA NRAS MITF TYR
7 cellular MP:0005384 10.47 MAP2K1 KIT MITF NRAS STK11 PTEN
8 mortality/aging MP:0010768 10.44 MAP2K1 KIT HRAS PIK3CA NRAS MITF
9 immune system MP:0005387 10.43 KIT MITF PIK3CA NRAS STK11 PTEN
10 embryo MP:0005380 10.42 MAP2K1 KIT PIK3CA NRAS MITF STK11
11 craniofacial MP:0005382 10.4 MAP2K1 KIT HRAS NRAS MITF TYR
12 hematopoietic system MP:0005397 10.39 KIT NRAS MITF STK11 PTEN CDK4
13 nervous system MP:0003631 10.33 HRAS MAP2K1 KIT MITF STK11 PTEN
14 digestive/alimentary MP:0005381 10.31 HRAS KIT MAP2K1 NRAS STK11 PTEN
15 neoplasm MP:0002006 10.29 MAP2K1 KIT HRAS PIK3CA NRAS TYR
16 muscle MP:0005369 10.24 KIT STK11 PTEN PIK3CA CDK4 BRAF
17 normal MP:0002873 10.22 MAP2K1 KIT HRAS NRAS MITF PTEN
18 hearing/vestibular/ear MP:0005377 10.19 KIT MITF MAP2K1 BRAF TYR CTNNB1
19 limbs/digits/tail MP:0005371 10.19 KIT NRAS MITF PTEN TYR CTNNB1
20 liver/biliary system MP:0005370 10.18 KIT NRAS STK11 PTEN CDK4 BRAF
21 no phenotypic analysis MP:0003012 10.17 KIT HRAS MITF NRAS STK11 PIK3CA
22 pigmentation MP:0001186 10.15 KIT NRAS MITF TYR PTEN CDKN2A
23 renal/urinary system MP:0005367 10.1 KIT HRAS STK11 PTEN CDK4 BRAF
24 reproductive system MP:0005389 10.07 MAP2K1 KIT MITF PIK3CA PTEN STK11
25 respiratory system MP:0005388 9.85 HRAS KIT STK11 PTEN BRAF CTNNB1
26 skeleton MP:0005390 9.8 MAP2K1 KIT HRAS PIK3CA NRAS MITF
27 vision/eye MP:0005391 9.4 MAP2K1 KIT PIK3CA NRAS MITF PTEN

Drugs & Therapeutics for Skin Melanoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Mekinist 18 49 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013

Drugs for Skin Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 657)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
4
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
6
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
7
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
8
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
9
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
10
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1195765-45-7 44462760 44516822
11
Palbociclib Approved, Investigational Phase 4,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
12
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
13
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
14
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 946414-94-4
15
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 85898-30-2, 110942-02-4
16
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
17
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
18
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
19
Simvastatin Approved Phase 4 79902-63-9 54454
20
Aminolevulinic acid Approved Phase 4,Phase 2,Not Applicable 106-60-5 137
21
Etanercept Approved, Investigational Phase 4 185243-69-0
22
Citalopram Approved Phase 4 59729-33-8 2771
23
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
24
Adalimumab Approved Phase 4 331731-18-1 16219006
25
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
26
Olaparib Approved Phase 4,Phase 1 763113-22-0 23725625
27
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
28
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 60-00-4, 62-33-9 6049
29
Pentetic acid Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 67-43-6
30
Crizotinib Approved Phase 4,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
31
Ceritinib Approved Phase 4,Phase 2,Early Phase 1 1032900-25-6
32
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
33
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
34
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871
35
Lapatinib Approved March 2007, Investigational Phase 4,Phase 3,Phase 2 231277-92-2, 388082-78-8 208908 9941095
36 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable
37 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Imatinib Mesylate Phase 4,Phase 2,Phase 1 220127-57-1 123596
39 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
40 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
45 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
47 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
48 Dermatologic Agents Phase 4,Phase 1,Phase 2,Not Applicable
49 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2462)
# Name Status NCT ID Phase Drugs
1 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
2 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
3 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Completed NCT01515189 Phase 4
4 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
5 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
6 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
7 Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
8 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection Completed NCT02476357 Phase 4
9 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
10 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
11 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
12 Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery Completed NCT00656292 Phase 4 Simvastatin;Placebo
13 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
14 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
15 Flu Vaccine Responses in the Setting of Melanoma Treatment Recruiting NCT03315975 Phase 4
16 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
17 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
18 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
19 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
20 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
21 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
22 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
23 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 Not yet recruiting NCT03313544 Phase 4 Nivolumab
24 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
25 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
26 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
27 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
28 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
29 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
30 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
31 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
32 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit Unknown status NCT01280565 Phase 3 masitinib;Dacarbazine
33 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride
34 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
35 Vaccine Therapy for Patients With Stage IV Melanoma Unknown status NCT00052156 Phase 3
36 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
37 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
38 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
39 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
40 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
41 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
42 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology Unknown status NCT00207298 Phase 3
43 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
44 PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) Completed NCT00221702 Phase 3 PegIntron;intron A
45 Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin Completed NCT00003444 Phase 3
46 Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma Completed NCT01989572 Phase 3
47 Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Completed NCT00019682 Phase 3 Montanide ISA 51 VG
48 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma Completed NCT01245062 Phase 3 GSK1120212;Chemotherapy
49 Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00110019 Phase 3 Carboplatin;Paclitaxel;Sorafenib Tosylate
50 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma Completed NCT00094653 Phase 3 MDX-010 (anti-CTLA4) monoclonal antibody

Search NIH Clinical Center for Skin Melanoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: melanoma, cutaneous malignant

Genetic Tests for Skin Melanoma

Genetic tests related to Skin Melanoma:

# Genetic test Affiliating Genes
1 Cutaneous Melanoma 29

Anatomical Context for Skin Melanoma

MalaCards organs/tissues related to Skin Melanoma:

41
Skin, Brain, Lung, T Cells, Lymph Node, Liver, Kidney

Publications for Skin Melanoma

Articles related to Skin Melanoma:

(show top 50) (show all 639)
# Title Authors Year
1
Targeted Photodynamic-Induced Singlet Oxygen Production by Peptide-Conjugated Biodegradable Nanoparticles for Treatment of Skin Melanoma. ( 29885810 )
2018
2
Pyoderma gangrenosum with its subtype affecting oral mucosa pyostomatitis vegetans following skin melanoma surgical excision in a patient with ulcerative colitis: a case report. ( 29760625 )
2018
3
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. ( 29794562 )
2018
4
Oral contraceptive use and cutaneous melanoma risk: A french prospective cohort study. ( 29978471 )
2018
5
Potential role of cyclin F mRNA expression in the survival of skin melanoma patients: Comprehensive analysis of the pathways altered due to cyclin F upregulation. ( 29767233 )
2018
6
Macrophages in skin melanoma-the key element in melanomagenesis. ( 29552183 )
2018
7
Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013-2016. ( 29120964 )
2018
8
Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. ( 28466785 )
2017
9
Clinicopathological features and clinical outcomes associated with TP53 and BRAF(N)(on-)(V)(600) mutations in cutaneous melanoma patients. ( 27911979 )
2017
10
Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma. ( 27666765 )
2017
11
A first case report of rare synchronous double cancers: malignant cutaneous melanoma and gastrointestinal stromal tumor. ( 28951716 )
2017
12
Rapid development of cutaneous melanoma metastases after herpes zoster infection in a radiotherapy field. ( 28940227 )
2017
13
Seasonality of birth for skin melanoma deserves further investigation. ( 28338933 )
2017
14
Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. ( 27956260 )
2017
15
Natural Compound Licochalcone B Induced Extrinsic and Intrinsic Apoptosis in Human Skin Melanoma (A375) and Squamous Cell Carcinoma (A431) Cells. ( 29027311 )
2017
16
Cutaneous Melanoma in Association With Ichthyosis Vulgaris. ( 28902080 )
2017
17
Review and proposal of regional surgical management for melanoma: revisiting of integumentectomy and incontinuity dissection in treatment of skin melanoma. ( 28064397 )
2017
18
Cytotoxicity of Labruscol, a New Resveratrol Dimer Produced by Grapevine Cell Suspensions, on Human Skin Melanoma Cancer Cell Line HT-144. ( 29120391 )
2017
19
Comparative study of head and neck mucosal melanoma in 66 patients vs 226 patients with cutaneous melanoma: A survival analysis. ( 28986955 )
2017
20
Health and Economic Burden of Skin Melanoma in Croatia - Cost-of-illness Study. ( 28511743 )
2017
21
Down-regulated miR-23a Contributes to the Metastasis of Cutaneous Melanoma by Promoting Autophagy. ( 28740547 )
2017
22
Cutaneous melanoma in Birt-Hogg-DubAc syndrome - part of the clinical spectrum? ( 28869776 )
2017
23
Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. ( 28787433 )
2017
24
PET Scan Misses Cutaneous Melanoma Metastasis with Significant Tumour Size and Tumour Thickness. ( 29362627 )
2017
25
Do polychlorinated biphenyls cause cancer? A systematic review and meta-analysis of epidemiological studies on risk of cutaneous melanoma and non-Hodgkin lymphoma. ( 28535466 )
2017
26
TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear. ( 28849221 )
2017
27
CDKN2A and MC1R variants found in Cypriot patients diagnosed with cutaneous melanoma. ( 28360400 )
2017
28
Expression of Antimicrobial Peptides by Uveal and Cutaneous Melanoma Cells and Investigation of Their Role in Tumor Cell Migration and Vasculogenic Mimicry. ( 28910167 )
2017
29
Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma. ( 29071268 )
2017
30
SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma. ( 28662141 )
2017
31
Incidence trends and survival of skin melanoma and squamous cell carcinoma in Cluj County, Romania. ( 28914690 )
2017
32
Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma. ( 28092675 )
2017
33
ZNF23 Suppresses Cutaneous Melanoma Cell Malignancy via Mitochondria-Dependent Pathway. ( 28848158 )
2017
34
Reply to: Seasonality of birth for skin melanoma deserves further investigation. ( 28338928 )
2017
35
Metallic copper nanoparticle induces apoptosis in human skin melanoma, A-375 cell line. ( 28067213 )
2017
36
NFa89I_B inhibition is associated with OPN/MMPa899 downregulation in cutaneous melanoma. ( 28075446 )
2017
37
The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy. ( 29310328 )
2017
38
Cutaneous Melanoma with Brain Metastasis: Report of 193 Patients with New Observations. ( 27213536 )
2016
39
The genomic landscape of cutaneous melanoma. ( 26833684 )
2016
40
Expression of Molecular Markers of Angiogenesis, Lymphangiogenesis, and Proliferation Depending on the Stage of Skin Melanoma. ( 27590758 )
2016
41
Low Expression of Mir-137 Predicts Poor Prognosis in Cutaneous Melanoma Patients. ( 26763596 )
2016
42
appendix 2: Cutaneous melanoma (2): eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Melanoma). ( 27664250 )
2016
43
Mutation Scanning of D1705 and D1709 in the RNAse IIIb Domain of MicroRNA Processing Enzyme Dicer in Cutaneous Melanoma. ( 26683837 )
2016
44
Bilateral Ischemic Retinal Vasculitis in Metastatic Cutaneous Melanoma Patient Treated with Dabrafenib and Trametinib: A Case Report. ( 27973971 )
2016
45
Decreased expression of hyaluronan synthase 1 and 2 associates with poor prognosis in cutaneous melanoma. ( 27184066 )
2016
46
Non-genetic risk factors for cutaneous melanoma and keratinocyte skin cancers: An umbrella review of meta-analyses. ( 27663092 )
2016
47
Fasting boosts sensitivity of human skin melanoma to cisplatin-induced cell death. ( 27693581 )
2016
48
EMMPRIN/CD147 is an independent prognostic biomarker in cutaneous melanoma. ( 27060463 )
2016
49
Quantitative assessment of the influence of X-ray repair cross-complementing group 3 rs861539 polymorphism and cutaneous melanoma susceptibility. ( 26922354 )
2016
50
BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin? ( 26980024 )
2016

Variations for Skin Melanoma

ClinVar genetic disease variations for Skin Melanoma:

6
(show top 50) (show all 343)
# Gene Variation Type Significance SNP ID Assembly Location
1 STK11 NM_000455.4(STK11): c.580G> T (p.Asp194Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913315 GRCh37 Chromosome 19, 1220487: 1220487
2 STK11 NM_000455.4(STK11): c.580G> T (p.Asp194Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913315 GRCh38 Chromosome 19, 1220488: 1220488
3 PTEN NM_000314.6(PTEN): c.633C> A (p.Cys211Ter) single nucleotide variant Pathogenic rs121909232 GRCh37 Chromosome 10, 89712015: 89712015
4 PTEN NM_000314.6(PTEN): c.633C> A (p.Cys211Ter) single nucleotide variant Pathogenic rs121909232 GRCh38 Chromosome 10, 87952258: 87952258
5 PTEN NM_000314.6(PTEN): c.55G> A (p.Asp19Asn) single nucleotide variant Pathogenic rs121909233 GRCh37 Chromosome 10, 89624281: 89624281
6 PTEN NM_000314.6(PTEN): c.55G> A (p.Asp19Asn) single nucleotide variant Pathogenic rs121909233 GRCh38 Chromosome 10, 87864524: 87864524
7 PTEN NM_000314.6(PTEN): c.649G> A (p.Val217Ile) single nucleotide variant Pathogenic rs121909234 GRCh37 Chromosome 10, 89717624: 89717624
8 PTEN NM_000314.6(PTEN): c.649G> A (p.Val217Ile) single nucleotide variant Pathogenic rs121909234 GRCh38 Chromosome 10, 87957867: 87957867
9 CDKN2A NM_000077.4(CDKN2A): c.238C> T (p.Arg80Ter) single nucleotide variant Likely pathogenic,risk factor rs121913388 GRCh37 Chromosome 9, 21971120: 21971120
10 CDKN2A NM_000077.4(CDKN2A): c.238C> T (p.Arg80Ter) single nucleotide variant Likely pathogenic,risk factor rs121913388 GRCh38 Chromosome 9, 21971121: 21971121
11 CDKN2A NM_000077.4(CDKN2A): c.238C> T (p.Arg80Ter) single nucleotide variant Likely pathogenic,risk factor rs121913388 NCBI36 Chromosome 9, 21961120: 21961120
12 CDKN2A NM_000077.4(CDKN2A): c.301G> T (p.Gly101Trp) single nucleotide variant risk factor rs104894094 GRCh37 Chromosome 9, 21971057: 21971057
13 CDKN2A NM_000077.4(CDKN2A): c.301G> T (p.Gly101Trp) single nucleotide variant risk factor rs104894094 GRCh38 Chromosome 9, 21971058: 21971058
14 HRAS NM_005343.3(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
15 HRAS NM_005343.3(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
16 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
17 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
18 KIT NM_000222.2(KIT): c.1676T> A (p.Val559Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh37 Chromosome 4, 55593610: 55593610
19 KIT NM_000222.2(KIT): c.1676T> A (p.Val559Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh38 Chromosome 4, 54727444: 54727444
20 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
21 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
22 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
23 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
24 KIT NM_000222.2(KIT): c.1676T> C (p.Val559Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh37 Chromosome 4, 55593610: 55593610
25 KIT NM_000222.2(KIT): c.1676T> C (p.Val559Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh38 Chromosome 4, 54727444: 54727444
26 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh37 Chromosome 4, 55594221: 55594221
27 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh38 Chromosome 4, 54728055: 54728055
28 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
29 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh38 Chromosome 1, 114716124: 114716124
30 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
31 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
32 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
33 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
34 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
35 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
36 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605
37 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
38 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh38 Chromosome 7, 140753334: 140753334
39 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
40 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh38 Chromosome 7, 140753345: 140753345
41 BRAF NM_004333.4(BRAF): c.1789C> G (p.Leu597Val) single nucleotide variant Pathogenic rs121913369 GRCh37 Chromosome 7, 140453146: 140453146
42 BRAF NM_004333.4(BRAF): c.1789C> G (p.Leu597Val) single nucleotide variant Pathogenic rs121913369 GRCh38 Chromosome 7, 140753346: 140753346
43 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
44 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh38 Chromosome 7, 140781603: 140781603
45 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
46 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh38 Chromosome 7, 140753354: 140753354
47 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
48 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
49 CDK4 NM_000075.3(CDK4): c.71G> A (p.Arg24His) single nucleotide variant Likely pathogenic,risk factor rs104894340 GRCh37 Chromosome 12, 58145430: 58145430
50 CDK4 NM_000075.3(CDK4): c.71G> A (p.Arg24His) single nucleotide variant Likely pathogenic,risk factor rs104894340 GRCh38 Chromosome 12, 57751647: 57751647

Cosmic variations for Skin Melanoma:

9
(show top 50) (show all 1910)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5611082 TRRAP skin,trunk,malignant melanoma,NS c.100C>T p.P34S 7:98881250-98881250 12
2 COSM1176879 TRRAP skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 7:98930064-98930064 12
3 COSM328254 TNC skin,trunk,malignant melanoma,NS c.1342C>G p.R448G 9:115086389-115086389 12
4 COSM5610746 TBX22 skin,trunk,malignant melanoma,NS c.1352G>T p.G451V 23:80030900-80030900 12
5 COSM5610663 SMG7 skin,trunk,malignant melanoma,NS c.2811C>T p.F937F 1:183549276-183549276 12
6 COSM5610425 PTPRK skin,trunk,malignant melanoma,NS c.2737G>A p.A913T 6:127996931-127996931 12
7 COSM5610317 PTPRD skin,trunk,malignant melanoma,NS c.2595G>A p.M865I 9:8486222-8486222 12
8 COSM5142 PTEN skin,trunk,malignant melanoma,NS c.112C>T p.P38S 10:87894057-87894057 12
9 COSM231641 PREX2 skin,trunk,malignant melanoma,NS c.1387C>T p.R463C 8:68069080-68069080 12
10 COSM584 NRAS skin,trunk,malignant melanoma,NS c.182A>G p.Q61R 1:114713908-114713908 12
11 COSM585 NRAS skin,trunk,malignant melanoma,NS c.183A>T p.Q61H 1:114713907-114713907 12
12 COSM571 NRAS skin,trunk,malignant melanoma,NS c.37G>A p.G13S 1:114716124-114716124 12
13 COSM5049807 NF1 skin,ear,malignant melanoma,NS c.3097C>T p.Q1033* 17:31230366-31230366 12
14 COSM5609545 NF1 skin,trunk,malignant melanoma,NS c.7189+1G>A p.? 17:31343136-31343136 12
15 COSM5049808 NF1 skin,ear,malignant melanoma,NS c.3652C>T p.Q1218* 17:31233157-31233157 12
16 COSM6503455 NF1 skin,trunk,malignant melanoma,NS c.2131C>T p.R711C 17:31226564-31226564 12
17 COSM5609467 MTOR skin,trunk,malignant melanoma,NS c.2638A>G p.T880A 1:11231311-11231311 12
18 COSM5609451 MSH6 skin,trunk,malignant melanoma,NS c.4004A>G p.E1335G 2:47806781-47806781 12
19 COSM232755 MAP2K1 skin,trunk,malignant melanoma,NS c.607G>A p.E203K 15:66481793-66481793 12
20 COSM5609259 KRAS skin,trunk,malignant melanoma,NS c.130G>A p.V44I 12:25227394-25227394 12
21 COSM5609255 KIT skin,trunk,malignant melanoma,NS c.575G>A p.G192D 4:54698521-54698521 12
22 COSM5609145 IL36A skin,trunk,malignant melanoma,NS c.359C>T p.S120F 2:113007926-113007926 12
23 COSM110485 GRIN2A skin,ear,malignant melanoma,NS c.3217G>A p.E1073K 16:9764327-9764327 12
24 COSM5609011 GRIN2A skin,trunk,malignant melanoma,NS c.2252G>A p.G751E 16:9798381-9798381 12
25 COSM109660 GRIN2A skin,ear,malignant melanoma,NS c.4097C>T p.P1366L 16:9763447-9763447 12
26 COSM5608954 GNAQ skin,trunk,malignant melanoma,NS c.264G>T p.Q88H 9:77922218-77922218 12
27 COSM1205523 EPHB4 skin,trunk,malignant melanoma,NS c.2177C>T p.S726L 7:100807522-100807522 12
28 COSM5608400 EPHA3 skin,trunk,malignant melanoma,NS c.2525G>A p.R842Q 3:89450205-89450205 12
29 COSM141892 CNR1 skin,ear,malignant melanoma,NS c.145C>T p.P49S 6:88145130-88145130 12
30 COSM141856 CHRM3 skin,ear,malignant melanoma,NS c.1741T>A p.F581I 1:239909192-239909192 12
31 COSM12503 CDKN2A skin,trunk,malignant melanoma,NS c.334C>G p.R112G 9:21971025-21971025 12
32 COSM13830 CDKN2A skin,trunk,malignant melanoma,NS c.341C>A p.P114H 9:21971018-21971018 12
33 COSM13281 CDKN2A skin,trunk,malignant melanoma,NS c.205G>T p.E69* 9:21971154-21971154 12
34 COSM476 BRAF skin,trunk,malignant melanoma,NS c.1799T>A p.V600E 7:140753336-140753336 12
35 COSM471 BRAF skin,ear,malignant melanoma,NS c.1790T>G p.L597R 7:140753345-140753345 12
36 COSM27639 BRAF skin,ear,malignant melanoma,NS c.1780G>A p.D594N 7:140753355-140753355 12
37 COSM1448615 BRAF skin,trunk,malignant melanoma,NS c.1390G>A p.G464R 7:140781618-140781618 12
38 COSM1125 BRAF skin,ear,malignant melanoma,NS c.1790T>A p.L597Q 7:140753345-140753345 12
39 COSM478 BRAF skin,ear,malignant melanoma,NS c.1801A>G p.K601E 7:140753334-140753334 12
40 COSM5608955 skin,trunk,malignant melanoma,NS c.177G>T p.Q59H 9:77922218-77922218 12
41 COSM1645467 skin,trunk,malignant melanoma,NS c.856G>A p.E286K 17:7673764-7673764 12
42 COSM99924 skin,trunk,malignant melanoma,NS c.856G>A p.E286K 17:7673764-7673764 12
43 COSM5610316 skin,trunk,malignant melanoma,NS c.2595G>A p.M865I 9:8486222-8486222 12
44 COSM5610424 skin,trunk,malignant melanoma,NS c.2737G>A p.A913T 6:127996931-127996931 12
45 COSM1176880 skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 7:98930064-98930064 12
46 COSM231642 skin,trunk,malignant melanoma,NS c.1387C>T p.R463C 8:68069080-68069080 12
47 COSM5610426 skin,trunk,malignant melanoma,NS c.2773G>A p.A925T 6:127996931-127996931 12
48 COSM5609258 skin,trunk,malignant melanoma,NS c.130G>A p.V44I 12:25227394-25227394 12
49 COSM5611083 skin,trunk,malignant melanoma,NS c.100C>T p.P34S 7:98881250-98881250 12
50 COSM5609544 skin,trunk,malignant melanoma,NS c.7189+1G>A p.? 17:31343136-31343136 12

Expression for Skin Melanoma

Search GEO for disease gene expression data for Skin Melanoma.

Pathways for Skin Melanoma

Pathways related to Skin Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 127)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.29 BRAF CDK4 CDKN2B CTNNB1 GNA11 GNAQ
2
Show member pathways
13.96 BRAF CDK4 CDKN2A CDKN2B CTNNB1 FBN1
3
Show member pathways
13.82 BRAF CDK4 CDKN2A CDKN2B GNA11 HRAS
4
Show member pathways
13.6 BRAF CDK4 CTNNB1 HRAS KIT MAP2K1
5
Show member pathways
13.51 BRAF CTNNB1 FBN1 GNA11 HRAS MAP2K1
6
Show member pathways
13.19 BRAF FBN1 GNA11 HRAS KIT MAP2K1
7
Show member pathways
13.15 GNA11 HRAS KIT MAP2K1 NRAS STK11
8
Show member pathways
13.15 BRAF CDKN2A CTNNB1 GNA11 HRAS MAP2K1
9
Show member pathways
13.13 GNA11 GNAQ HRAS MAP2K1 NRAS PIK3CA
10
Show member pathways
13.13 BRAF CTNNB1 GNA11 GNAQ HRAS MAP2K1
11
Show member pathways
13.08 CDK4 CTNNB1 HRAS KIT MAP2K1 NRAS
12
Show member pathways
13.05 BRAF CDK4 CTNNB1 HRAS MAP2K1 NRAS
13
Show member pathways
13.05 BRAF GNA11 GNAQ HRAS KIT MAP2K1
14
Show member pathways
13.03 BRAF CTNNB1 HRAS MAP2K1 NRAS PIK3CA
15
Show member pathways
13.02 BRAF HRAS MAP2K1 NRAS PIK3CA PTEN
16
Show member pathways
13 BRAF GNA11 HRAS MAP2K1 NRAS PIK3CA
17
Show member pathways
12.99 BRAF GNA11 HRAS MAP2K1 NRAS PIK3CA
18
Show member pathways
12.94 BRAF GNA11 HRAS MAP2K1 MITF NRAS
19
Show member pathways
12.93 BRAF GNA11 GNAQ HRAS MAP2K1 NRAS
20
Show member pathways
12.92 BRAF CTNNB1 GNA11 HRAS MAP2K1 NRAS
21
Show member pathways
12.89 CDKN2A HRAS MAP2K1 NRAS PIK3CA
22
Show member pathways
12.88 BRAF HRAS MAP2K1 NRAS PTEN
23
Show member pathways
12.88 BRAF CDK4 CDKN2A CTNNB1 HRAS KIT
24 12.86 BRAF HRAS KIT MAP2K1 NRAS
25
Show member pathways
12.85 BRAF GNA11 GNAQ HRAS MAP2K1 NRAS
26
Show member pathways
12.84 BRAF CTNNB1 HRAS MAP2K1 NRAS PIK3CA
27
Show member pathways
12.83 HRAS KIT NRAS PIK3CA PTEN
28
Show member pathways
12.83 BRAF CTNNB1 GNAQ HRAS KIT MAP2K1
29
Show member pathways
12.77 BRAF GNA11 HRAS MAP2K1 NRAS
30
Show member pathways
12.77 BRAF CDK4 CDKN2A CDKN2B HRAS MAP2K1
31
Show member pathways
12.75 CTNNB1 GNA11 GNAQ HRAS MAP2K1 NRAS
32 12.73 BRAF HRAS MAP2K1 NRAS PIK3CA
33
Show member pathways
12.7 HRAS MAP2K1 NRAS PIK3CA PTEN
34
Show member pathways
12.69 CDK4 CTNNB1 HRAS MAP2K1 NRAS PIK3CA
35
Show member pathways
12.67 BRAF CTNNB1 HRAS MAP2K1 NRAS PIK3CA
36 12.65 CDKN2A HRAS MAP2K1 NRAS PIK3CA PTEN
37
Show member pathways
12.63 BRAF HRAS MAP2K1 NRAS PIK3CA
38
Show member pathways
12.63 BRAF CDK4 CDKN2A CDKN2B CTNNB1 GNA11
39
Show member pathways
12.61 HRAS MAP2K1 NRAS PIK3CA PTEN
40
Show member pathways
12.61 BRAF HRAS MAP2K1 NRAS PIK3CA PTEN
41
Show member pathways
12.6 BRAF HRAS MAP2K1 NRAS PIK3CA
42
Show member pathways
12.57 CTNNB1 HRAS MAP2K1 NRAS PIK3CA
43
Show member pathways
12.56 BRAF CDK4 CDKN2A CDKN2B CTNNB1 HRAS
44
Show member pathways
12.55 BRAF HRAS MAP2K1 MITF NRAS
45
Show member pathways
12.55 CDK4 HRAS MAP2K1 NRAS PIK3CA
46
Show member pathways
12.53 HRAS KIT MAP2K1 NRAS PIK3CA
47
Show member pathways
12.53 BRAF CTNNB1 HRAS MAP2K1 PIK3CA
48 12.53 CDK4 CDKN2A CDKN2B CTNNB1 HRAS NRAS
49
Show member pathways
12.52 BRAF HRAS MAP2K1 NRAS
50
Show member pathways
12.52 BRAF HRAS MAP2K1 NRAS PIK3CA PTEN

GO Terms for Skin Melanoma

Cellular components related to Skin Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 BRAF CDK4 CDKN2A CDKN2B CTNNB1 GNA11

Biological processes related to Skin Melanoma according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.97 BRAF CDK4 CDKN2A CDKN2B KIT MAP2K1
2 regulation of gene expression GO:0010468 9.96 CDK4 CTNNB1 MITF PIK3CA
3 MAPK cascade GO:0000165 9.95 BRAF HRAS KIT MAP2K1 NRAS
4 regulation of cell proliferation GO:0042127 9.93 BRAF CDK4 CTNNB1 KIT MITF
5 T cell receptor signaling pathway GO:0050852 9.91 BRAF HRAS PIK3CA STK11
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 BRAF HRAS KIT MAP2K1 PTEN
7 skeletal system development GO:0001501 9.89 CTNNB1 FBN1 GNA11 GNAQ
8 activation of protein kinase activity GO:0032147 9.85 MAP2K1 PIK3CA STK11
9 canonical Wnt signaling pathway GO:0060070 9.84 CTNNB1 PTEN STK11
10 Ras protein signal transduction GO:0007265 9.83 CDKN2A HRAS NRAS
11 cell cycle arrest GO:0007050 9.83 CDKN2A CDKN2B HRAS MAP2K1 STK11
12 epidermal growth factor receptor signaling pathway GO:0007173 9.8 HRAS NRAS PIK3CA
13 heart development GO:0007507 9.8 CTNNB1 FBN1 GNA11 GNAQ MAP2K1 PTEN
14 negative regulation of cell proliferation GO:0008285 9.8 CDKN2A CDKN2B CTNNB1 HRAS MAP2K1 PTEN
15 pigmentation GO:0043473 9.75 KIT MITF TYR
16 ERBB2 signaling pathway GO:0038128 9.74 HRAS NRAS PIK3CA
17 positive regulation of axonogenesis GO:0050772 9.73 BRAF MAP2K1 STK11
18 thymus development GO:0048538 9.71 BRAF CTNNB1 MAP2K1 TYR
19 vasculature development GO:0001944 9.67 CTNNB1 PIK3CA STK11
20 somatic stem cell division GO:0048103 9.65 CDKN2A KIT
21 anoikis GO:0043276 9.65 PIK3CA STK11
22 cellular response to insulin-like growth factor stimulus GO:1990314 9.65 FBN1 PTEN
23 cellular senescence GO:0090398 9.65 CDKN2A HRAS MAP2K1
24 phototransduction, visible light GO:0007603 9.64 GNA11 GNAQ
25 entrainment of circadian clock GO:0009649 9.64 GNA11 GNAQ
26 developmental pigmentation GO:0048066 9.63 GNA11 GNAQ KIT
27 positive regulation of DNA-templated transcription, initiation GO:2000144 9.62 CTNNB1 MITF
28 trachea formation GO:0060440 9.62 CTNNB1 MAP2K1
29 myeloid progenitor cell differentiation GO:0002318 9.61 BRAF KIT
30 canonical Wnt signaling pathway involved in negative regulation of apoptotic process GO:0044336 9.58 CTNNB1 MITF
31 positive regulation of gene expression GO:0010628 9.56 BRAF CDKN2A CTNNB1 HRAS KIT MAP2K1
32 regulation of melanocyte differentiation GO:0045634 9.52 GNA11 GNAQ
33 regulation of axon regeneration GO:0048679 9.33 BRAF MAP2K1 PTEN
34 negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 8.92 CDK4 CDKN2A CDKN2B PTEN
35 signal transduction GO:0007165 10.29 BRAF CDK4 CTNNB1 GNA11 GNAQ HRAS
36 protein phosphorylation GO:0006468 10.08 BRAF CDK4 KIT MAP2K1 PIK3CA STK11
37 positive regulation of cell proliferation GO:0008284 10.07 CDK4 CTNNB1 HRAS KIT PTEN

Molecular functions related to Skin Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.77 BRAF CDK4 KIT MAP2K1 STK11
2 protein serine/threonine kinase activity GO:0004674 9.65 BRAF CDK4 MAP2K1 PIK3CA STK11
3 nucleotide binding GO:0000166 9.43 BRAF CDK4 HRAS KIT MAP2K1 NRAS
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.32 CDKN2A CDKN2B
5 kinase activity GO:0016301 9.23 BRAF CDK4 CDKN2A CDKN2B KIT MAP2K1
6 type 2A serotonin receptor binding GO:0031826 9.16 GNA11 GNAQ

Sources for Skin Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....